Axon Enterprise's Q4 results were strong, with revenue up 34% YoY and adjusted EPS up 84.1%. Read more to see what makes AXON ...

Meanwhile, Eli Lilly, AC Immune, Johnson & Johnson, Merck & Co, Anavex and Axon Neurosciences have other anti-tau drugs in early-stage clinical testing. Roche’s head of pharma partnering ...

including TauRx’ tau aggregation inhibitor LMTX which failed a trial in 2016 but is still in a phase 2/3 study due to read out next year, while Axon Neuroscience’s AADvac1 was also ...

In this article, we will take a look at where Axon Enterprise, Inc. (NASDAQ:AXON) stands against other stocks with the highest EPS growth during this period. The world has been embroiled in deadly ...

They focused on impaired mitochondrial transport in the axon, a portion of nerve cells ... are twisted fibers of another ...